Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

The immunostimulants 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-
21 are part of licensed or candidate vaccines. MPL and QS-21 directly affect the innate …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background Over the past decade malaria intervention coverage has been scaled up across
Africa. However, it remains unclear what overall reduction in transmission is achievable …

Background The candidate malaria vaccine RTS, S/AS01E has entered phase 3 trials, but
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …

Malaria caused by Plasmodium falciparum remains a major public health threat, especially
among children and pregnant women in Africa. An effective malaria vaccine would be a …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

Background We have shown that immunity to infection with Plasmodium falciparum can be
induced experimentally in malaria-naive volunteers through immunisation by bites of …

Early data emerging from the first phase 3 trial of a malaria vaccine are raising hopes that a
licensed vaccine will soon be available for use in endemic countries, but given the relatively …